Challenged claims of Trutek Corp.'s patent directed to electrostatically charged nasal application products that reduce the inflow of airborne contaminants to the nasal passages are unpatentable as anticipated by and obvious over prior art, the Patent Trial and Appeal Board determined, in an inter partes review by Salvacion USA Inc. The board said that the challenged claims are unpatentable as anticipated by and obvious over various combinations of prior art, including prior art that discloses anti-viral pharmaceutical compositions, non-toxic antimicrobial compositions and methods of use, and electrostatically charged nasal application product with increased strength. And the board dismissed Salvacion’s motions ...